155 related articles for article (PubMed ID: 8729949)
21. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
Gatzemeier U; Heckmayer M; Neuhauss R; Schlüter I; von Pawel J; Wagner H; Dreps A
Semin Oncol; 1995 Dec; 22(6 Suppl 15):24-8. PubMed ID: 8643966
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687
[TBL] [Abstract][Full Text] [Related]
23. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
Holmes FA
Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702
[TBL] [Abstract][Full Text] [Related]
24. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Dieras V; Chevallier B; Kerbrat P; Krakowski I; Roche H; Misset JL; Lentz MA; Azli N; Murawsky M; Riva A; Pouillart P; Fumoleau P
Br J Cancer; 1996 Aug; 74(4):650-6. PubMed ID: 8761385
[TBL] [Abstract][Full Text] [Related]
25. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
[TBL] [Abstract][Full Text] [Related]
26. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
Borovik R; Steiner M; Atad J; Sneiderman B; Rosenberg T; Palti S
Harefuah; 1998 Apr; 134(8):605-8, 671. PubMed ID: 10911422
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer.
Anderson SE; O'Reilly EM; Kelsen DP; Ilson DH
Cancer Invest; 2003; 21(4):512-6. PubMed ID: 14533440
[TBL] [Abstract][Full Text] [Related]
28. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
[TBL] [Abstract][Full Text] [Related]
29. Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
Shapiro JD; Millward MJ; Rischin D; Davison JD; Michael M; Francis PA; Ganju V; Toner GC
Aust N Z J Med; 1997 Feb; 27(1):40-4. PubMed ID: 9079252
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of semisynthetic paclitaxel in metastatic breast cancer.
Hudis C; Riccio L; Holmes F; Seidman A; Baselga J; Currie V; Fennelly D; Gilewski T; Moynahan M; Raptis G; Sklarin N; Surbone A; Uhlenhopp M; Maickel N; Yao TJ; Hellmann S; Usakewicz J; Hortobagyi G; Norton L
Eur J Cancer; 1997 Nov; 33(13):2198-202. PubMed ID: 9470806
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology group (ECOG) results.
Einzig AI; Lipsitz S; Wiernik PH; Benson AB
Invest New Drugs; 1995; 13(3):223-7. PubMed ID: 8729950
[TBL] [Abstract][Full Text] [Related]
32. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer.
Klaassen U; Harstrick A; Wilke H; Seeber S
Semin Oncol; 1996 Feb; 23(1 Suppl 1):44-7. PubMed ID: 8629037
[TBL] [Abstract][Full Text] [Related]
33. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
Holmes FA; Walters RS; Theriault RL; Forman AD; Newton LK; Raber MN; Buzdar AU; Frye DK; Hortobagyi GN
J Natl Cancer Inst; 1991 Dec; 83(24):1797-805. PubMed ID: 1683908
[TBL] [Abstract][Full Text] [Related]
35. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Valero V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand.
Bishop JF; Dewar J; Toner GC; Tattersall MH; Olver IN; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):19-23. PubMed ID: 9144686
[TBL] [Abstract][Full Text] [Related]
37. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.
Akerley W; Sikov WM; Cummings F; Safran H; Strenger R; Marchant D
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-87-S17-90. PubMed ID: 9374102
[TBL] [Abstract][Full Text] [Related]
38. Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer.
Wist EA; Sommer HH; Ostenstad B; Risberg T; Fjaestad K
Acta Oncol; 2004; 43(1):11-4. PubMed ID: 15068314
[TBL] [Abstract][Full Text] [Related]
39. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
40. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
Chevallier B; Fumoleau P; Kerbrat P; Dieras V; Roche H; Krakowski I; Azli N; Bayssas M; Lentz MA; Van Glabbeke M
J Clin Oncol; 1995 Feb; 13(2):314-22. PubMed ID: 7844592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
